Eight Immune Checkpoints: The Next Era of Cancer Immunotherapy

Immune checkpoint blockade transformed oncology by shifting therapy from direct tumor killing to reactivation of antitumor immunity. As immuno-oncology evolves, a broader network of inhibitory and metabolic checkpoints is reshaping how researchers think about resistance, biomarker-guided combinations, and durable tumor control.

Introduction

The advent of immune checkpoint blockade has revolutionized the therapeutic landscape of oncology. Rather than directly targeting tumor cells, checkpoint inhibitors unleash the intrinsic cytotoxic potential of the immune system, reawakening suppressed T cells to recognize and eliminate malignant cells. This conceptual leap—transforming the immune system from a bystander into the principal agent of tumor control—has produced durable remissions previously unattainable with chemotherapy or targeted therapy.

However, the immune system’s capacity for discrimination between “self” and “non-self” relies on inhibitory pathways that maintain tolerance and prevent autoimmunity. Cancer cells co-opt these same inhibitory mechanisms to create an immunosuppressive microenvironment that hinders effective antitumor responses. The clinical success of antibodies against CTLA-4 and PD-1 established immune checkpoints as the molecular “brakes” of the immune system, whose selective blockade can reprogram immune exhaustion into durable effector activity.

Yet, not all patients benefit equally. Resistance—both primary and acquired—reflects the plasticity of the tumor–immune interface and the redundancy among inhibitory pathways. Modern immuno-oncology thus seeks to map this complex network and identify new nodes of therapeutic control. This review discusses eight immune checkpoints—PD-1, PD-L1, LAG3, TIM-3, TIGIT, VISTA, IDO1, and BTLA—that collectively orchestrate immune activation, tolerance, and exhaustion. Their mechanistic diversity underscores the sophistication of immune regulation and heralds the next era of combinatorial immunotherapy.

PD-1: The Central Regulator of T-cell Exhaustion

Programmed cell death protein 1 (PD-1, Programmed Cell Death Protein 1) is a type I transmembrane receptor belonging to the CD28 family, expressed on activated T and B lymphocytes, NK cells, and some myeloid cells. Engagement of PD-1 with its ligands PD-L1 or PD-L2 recruits SHP-2 phosphatase to the cytoplasmic immunoreceptor tyrosine-based motifs (ITIM and ITSM), dephosphorylating key TCR signaling intermediates such as CD3ζ, ZAP70, and CD28. The result is attenuation of downstream PI3K–AKT and MAPK cascades, metabolic reprogramming toward fatty acid oxidation, and suppression of effector functions including IFN-γ and granzyme B secretion.

Tumors exploit this pathway by overexpressing PD-L1, thereby inducing T-cell exhaustion characterized by reduced proliferation and effector capacity. PD-1 inhibitors such as Nivolumab, Pembrolizumab, and Cemiplimab restore T-cell activity and have achieved durable responses in melanoma, NSCLC, and renal carcinoma. Nonetheless, resistance may arise from defects in antigen presentation (β2M loss), JAK/STAT alterations, or compensatory upregulation of alternative checkpoints such as LAG3 and TIGIT.

According to Nature Reviews Immunology (2025)[1], recent cryo-EM and imaging studies reveal that PD-1 reorganizes the TCR microcluster to exclude co-stimulatory signals, establishing a spatial “immune synapse barrier.” Combination blockade of PD-1 with metabolic or co-stimulatory pathway modulators (OX40, 4-1BB) is now a leading strategy to overcome exhaustion.

PD-L1: The Ligand of Immune Suppression and Tumor Survival

Programmed death-ligand 1 (PD-L1, Programmed Death Ligand 1) is widely expressed on tumor and stromal cells and can be upregulated by inflammatory cytokines such as IFN-γ via JAK/STAT and IRF1 activation. PD-L1 not only inhibits PD-1–expressing T cells but also signals intrinsically within tumor cells to promote epithelial–mesenchymal transition (EMT), invasion, and apoptosis resistance. In macrophages and dendritic cells, PD-L1 regulates cytokine secretion, further shaping an immunosuppressive milieu.

Clinically, PD-L1 blockade with antibodies such as Atezolizumab, Durvalumab, and Avelumab has extended checkpoint therapy to patients whose tumors express high PD-L1 or exhibit adaptive immune resistance. However, PD-L1 expression alone is an imperfect biomarker due to intratumoral heterogeneity and dynamic regulation. Mechanistically, oncogenic signaling pathways (e.g., EGFR, ALK, and PTEN loss) also elevate PD-L1 transcription, linking oncogenesis to immune escape.

The Cell Reports Medicine (2024)[2] review highlights PD-L1’s cytoplasmic signaling functions, particularly its interaction with mTOR and autophagy regulators. Targeting PD-L1 alongside TGF-β or VEGF pathways may simultaneously remodel the stromal compartment and recondition immune infiltration—an emerging direction for next-generation immunotherapies.

LAG3: The Emerging Partner in Immune Exhaustion

Lymphocyte activation gene 3 (LAG3, Lymphocyte Activation Gene 3) structurally resembles CD4 and binds MHC class II molecules with higher affinity, directly interfering with T-cell receptor (TCR) signaling and antigen recognition. It is co-expressed with PD-1 on chronically stimulated CD8⁺ T cells, where it reinforces exhaustion by reducing calcium flux, NFAT activation, and IL-2 production. Beyond T cells, LAG3 is expressed on natural killer cells and plasmacytoid dendritic cells, modulating both adaptive and innate responses.

The therapeutic significance of LAG3 is now clinically validated. The combination of Nivolumab (anti–PD-1) and Relatlimab (anti–LAG3) has shown superior efficacy in advanced melanoma compared to monotherapy. Other LAG3 antagonists, such as Fianlimab and Ieramilimab, are being explored in lung, gastric, and hematologic malignancies. Resistance mechanisms include upregulation of alternative inhibitory receptors such as TIM-3 and metabolic suppression within the TME.

Cancer Immunology Research (2025)[3] emphasizes that LAG3 expression marks both dysfunctional effector T cells and immunosuppressive regulatory T cells (Tregs). Dual blockade with PD-1 can rejuvenate the exhausted compartment while rebalancing suppressive immune subsets—an essential component of durable antitumor immunity.

TIM-3: A Multifunctional Checkpoint in T-cell Dysfunction

T-cell immunoglobulin and mucin-domain containing 3 (TIM-3, T-cell Immunoglobulin and Mucin-domain 3) is a versatile inhibitory receptor expressed on exhausted CD8⁺ T cells, dendritic cells, and monocytes. TIM-3 interacts with multiple ligands—Galectin-9, CEACAM1, phosphatidylserine, and HMGB1—mediating immune suppression via diverse mechanisms. Galectin-9 binding triggers Ca²⁺ influx and apoptosis in Th1 cells, while CEACAM1 co-expression promotes internalization of the receptor-ligand complex, blunting TCR signaling.

TIM-3 also shapes innate immunity: in macrophages, it promotes the M2-polarized phenotype, and in dendritic cells, it suppresses type I interferon production, dampening antigen presentation. Blockade of TIM-3 has shown synergy with PD-1 inhibition, especially in tumors where dual expression identifies a terminally exhausted T-cell population resistant to single-agent therapy.

The Frontiers in Immunology (2024)[4] review reveals that TIM-3 signaling intersects with mitochondrial metabolism and ROS regulation, influencing cellular energetics in exhausted T cells. Therapeutic strategies combining TIM-3 inhibition with metabolic modulators such as PGC1α agonists may restore mitochondrial fitness and effector function.

TIGIT: The Co-inhibitory Node Balancing Immune Activation

TIGIT (T-cell Immunoreceptor with Ig and ITIM domains) acts as a crucial checkpoint on activated T cells, Tregs, and NK cells, competing with the co-stimulatory receptor CD226 for binding to the ligands CD155 (PVR) and CD112 (Nectin-2). The outcome depends on the relative expression and affinity of these receptors: TIGIT engagement recruits SHIP1 and Grb2 to its ITIM/ITSM motifs, suppressing PI3K and MAPK signaling and reducing cytotoxic granule release.

Therapeutic TIGIT blockade seeks to restore CD226-mediated activation. Tiragolumab, combined with Atezolizumab, has produced significant clinical benefit in PD-L1–high NSCLC. However, adaptive resistance can emerge through CD226 downregulation or upregulation of related inhibitory receptors such as CD96.

In Nature Medicine (2025)[5], structural studies delineate the TIGIT–CD155 interface, showing that subtle conformational adjustments dictate binding affinity. The review proposes designing bispecific antibodies that simultaneously engage PD-1 and TIGIT to achieve cooperative signaling modulation and sustained tumor control.

VISTA: The Context-Dependent Gatekeeper of Immune Quiescence

V-domain immunoglobulin suppressor of T-cell activation (VISTA, V-domain Ig Suppressor of T-cell Activation) is a pH-sensitive immunoregulatory molecule expressed predominantly on myeloid cells, naïve T cells, and regulatory T cells. VISTA maintains immune homeostasis by inhibiting T-cell proliferation and cytokine release under acidic conditions typical of the tumor microenvironment. Its unique pH-dependent conformational dynamics allow VISTA to function as both a ligand and receptor.

Unlike PD-1 or CTLA-4, which act at later stages of T-cell activation, VISTA operates during initial priming and within the myeloid compartment. Elevated VISTA expression in tumor-associated macrophages and MDSCs correlates with resistance to PD-1 blockade. Preclinical antibodies such as CI-8993 and KVA12123 have demonstrated tumor regression in checkpoint-refractory models.

Cancer Cell (2024)[6] reports that VISTA links metabolic and immune regulation: its proton-sensing mechanism integrates extracellular acidity with immune suppression, suggesting that targeting VISTA could normalize the TME pH and potentiate T-cell reactivation when combined with PD-1 inhibitors.

IDO1: The Metabolic Enzyme Driving Immune Tolerance

Indoleamine 2,3-dioxygenase 1 (IDO1, Indoleamine 2,3-Dioxygenase 1) catalyzes the first and rate-limiting step of tryptophan catabolism along the kynurenine pathway. Depletion of tryptophan impairs effector T-cell proliferation, while accumulation of kynurenine activates the aryl hydrocarbon receptor (AHR), promoting differentiation of regulatory T cells and myeloid-derived suppressor cells. Thus, IDO1 acts as a “metabolic checkpoint” coupling nutrient availability to immune tolerance.

Although early IDO1 inhibitors such as Epacadostat failed in phase III trials when combined with PD-1 blockade, the mechanistic understanding of IDO1 signaling has expanded. Beyond enzymatic activity, IDO1 possesses non-catalytic scaffolding functions that influence STAT3 activation and dendritic cell tolerogenicity. New strategies include dual IDO1/TDO inhibitors, IDO1–AHR antagonists, and nanoparticle-based delivery to achieve localized inhibition.

The Trends in Immunology (2025)[7] review highlights that IDO1 expression can reprogram the myeloid compartment and suppress antigen presentation. Integrating metabolic reprogramming with checkpoint blockade may rejuvenate immune surveillance even in nutrient-depleted TMEs.

BTLA: The Inhibitory Receptor Bridging Innate and Adaptive Immunity

B and T lymphocyte attenuator (BTLA, B and T Lymphocyte Attenuator) is a co-inhibitory receptor in the CD28 superfamily that interacts with the TNFR family member HVEM (Herpesvirus Entry Mediator). The BTLA–HVEM axis establishes bidirectional signaling: BTLA delivers inhibitory signals to T cells through ITIM and ITSM motifs, while HVEM engagement triggers co-stimulatory responses in innate immune cells. This reciprocal regulation modulates crosstalk between adaptive and innate compartments, maintaining immune equilibrium.

BTLA is upregulated in chronically stimulated T cells and within immune-privileged tumor niches such as liver and bone marrow. Its sustained expression correlates with poor prognosis in hepatocellular carcinoma and B-cell lymphoma. Inhibiting BTLA/HVEM signaling enhances T-cell infiltration, cytokine production, and synergy with PD-1 blockade in preclinical studies.

The Annual Review of Immunology (2024)[8] article frames BTLA as a “bidirectional checkpoint” that integrates tolerance and activation cues. Therapeutic modulation—either blocking inhibitory signaling or promoting pro-inflammatory HVEM pathways—offers a nuanced approach to recalibrate immune balance in cancer.

Conclusion

The eight immune checkpoints explored—PD-1, PD-L1, LAG3, TIM-3, TIGIT, VISTA, IDO1, and BTLA—represent an interconnected system of inhibitory and metabolic pathways that govern immune homeostasis. Together, they demonstrate that immune evasion is a multi-layered process, driven by receptor redundancy, ligand diversity, and metabolic adaptation.

Clinically, the first generation of checkpoint inhibitors has proven that immune modulation can induce long-term remission even in metastatic cancer. However, therapeutic resistance, limited response rates, and immune-related adverse events reveal the need for precision immunotherapy guided by biomarkers and mechanistic insight. Future directions emphasize combination strategies—integrating checkpoint blockade with metabolic reprogramming, cytokine modulation, and adoptive T-cell or NK-cell therapy—to achieve sustained antitumor activity.

Furthermore, advances in single-cell multi-omics and spatial immunology now allow direct mapping of immune checkpoint expression at cellular and tissue resolution, uncovering the contextual dependencies that determine therapeutic response. Artificial intelligence–based modeling of ligand–receptor networks is expected to accelerate drug discovery and patient stratification.

Ultimately, the study of immune checkpoints transcends cancer therapy—it illuminates the fundamental principles of self-tolerance, immune memory, and tissue homeostasis. As next-generation immunotherapies evolve from empirical combination to rational orchestration, mastering these inhibitory networks will bring oncology closer to the ultimate goal: achieving durable, immune-mediated tumor eradication.

Frequently Asked Questions (FAQs)

References

1. Wei S.C., et al. PD-1 signaling and T-cell exhaustion: structural basis and therapeutic modulation. Nature Reviews Immunology 25, 110–132 (2025).
2. Sun C., et al. PD-L1 biology beyond immune evasion: implications for tumor metabolism and therapy. Cell Reports Medicine 5(3), 103211 (2024).
3. Andrews L.P., et al. LAG3 as a therapeutic target in cancer: biology, signaling, and clinical development. Cancer Immunology Research 13, 451–472 (2025).
4. Dixon K.O., et al. TIM-3: emerging mechanisms and therapeutic potential in exhausted T cells. Frontiers in Immunology 15, 1395–1418 (2024).
5. Chauvin J.M., et al. TIGIT and CD226: balancing immune activation in the tumor microenvironment. Nature Medicine 31, 12–31 (2025).
6. ElTanbouly M.A., et al. VISTA and the metabolic control of tumor immunity. Cancer Cell 42(2), 169–190 (2024).
7. Platten M., et al. IDO1 and tryptophan metabolism in cancer: therapeutic opportunities and challenges. Trends in Immunology 46(1), 45–64 (2025).
8. Krieg C., et al. BTLA/HVEM signaling: a bidirectional checkpoint in cancer immunology. Annual Review of Immunology 42, 301–324 (2024).